Brolucizumab in age-related macular degeneration, HAWK Study
3 October 2023
| Kurt Spiteri Cornish
|
Retina / Uvea / Vitreous
|
Neovascular age-related macular degeneration, aflibercept, anti-vascular endothelial growth factor therapy, brolucizumab, commercial formulation
The aim of the study was to collect additional data on efficacy and safety of brolucizumab 6mg intended for commercialization in age-related macular degeneration (AMD) (with an increase in pH and decrease in polysorbate concentration). The HAWK Study was a...
Effect of blue-light filtering intraocular lenses on age-related macular degeneration
7 April 2021
| Anna Song
|
Retina / Uvea / Vitreous
|
Age-related macular degeneration, Anti–vascular endothelial growth factor, Blue-light filtering, Cataract surgery, Choroidal neovascularization, Intraocular lens, Neovascular age-related macular degeneration
This is a retrospective cohort study evaluating whether blue-light filtering (BLF) intraocular lenses (IOL) offer prophylaxis for neovascular age-related macular degeneration (nAMD). The study included 11,397 eyes of 11,397 patients with a mean age of 75.4 ±8.3 years that underwent...
